Piper Sandler analyst James Fish maintains Fastly (NYSE:FSLY) with a Neutral and raises the price target from $10 to $14.
Coya Therapeutics Licenses Exclusive Worldwide Rights To Exosome Engineering Technology From Carnegie Mellon University
Supported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable engineering of exosomes with potential to target epitope driven
